On April 6, 2026, Renovare Therapeutics, a privately held biotechnology company pioneering regenerative therapeutics for osteoarthritis, announced its formal launch from stealth mode and collaboration with University of Colorado (CU) Boulder. Wilson Sonsini Goodrich & Rosati advised Renovare Therapeutics on the transaction.

CU Boulder was awarded a contract of up to $33.5 million from the Advanced Research Projects Agency for Health (ARPA-H). The non-dilutive funding, delivered under ARPA-H’s Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program, will support the continued development of lead product candidates through IND-enabling and first-in-human Phase 1 safety studies. Renovare Therapeutics will collaborate with CU Boulder to advance novel therapies toward commercialization.

The Wilson Sonsini team that advised Renovare Therapeutics on the transaction includes Brent Fassett and Preston Kramer.

For more information, please see Renovare Therapeutics’ news release.